Ivabradine — Discount Pricing
Ivabradine is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Ivabradine Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $103.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Ivabradine
Ivabradine is a prescription medication. Ask your doctor if Ivabradine is right for you.
How to Check Ivabradine Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Ivabradine at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Heart & Cardiovascular
What Ivabradine is approved for (FDA label)
Ivabradine tablets are a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) 1.1 Heart Failure in Adult Patients Ivabradine tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.
Source: Read the full FDA label on DailyMed. Label effective date: August 20, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Ivabradine (FDA label)
Ivabradine tablets 5 mg: orange colored, capsule shaped, film-coated tablets, functionally scored with debossing "M" & "I" on one side and "2" on other side. The tablet is scored and can be divided into equal halves to provide a 2.5 mg dose. 7.5 mg: orange colored, round shaped, film-coated tablets debossed with “MI” on one side and “1” on the other side. Tablets: 5 mg, 7.5 mg ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Ivabradine (FDA label)
Clinically significant adverse reactions that appear in other sections of the labeling include: • Atrial Fibrillation [ see Warnings and Precautions (5.2) ] • Bradycardia and Conduction Disturbances [ see Warnings and Precautions (5.3) ] Most common adverse reactions occurring in ≥ 1% of patients are bradycardia, hypertension, atrial fibrillation and luminous phenomena (phosphenes). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals, LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Ivabradine (FDA label)
Ivabradine is contraindicated in patients with: • Acute decompensated heart failure • Clinically significant hypotension • Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present • Clinically significant bradycardia [ see Warnings and Precautions (5.3) ] • Severe hepatic impairment [ see Use in Specific Populations (8.6) ] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [ see Drug Interactions (7.3) ] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [ see Drug Interactions (7.1) ] • Acute decompensated heart failure ( 4 ) • Clinically significant hypotension ( 4 ) • Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present ( 4 ) • Clinically significant bradycardia ( 4 ) • Severe hepatic impairment ( 4 ) • Heart rate maintained exclusively by the pacemaker ( 4 ) • In combination with strong cytochrome CYP3A4 inhibitors ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 676907d3-b374-4baa-8422-c04706409540. SPL document ID: c154911d-3174-409f-9619-3fe38dda4dbd. Label effective date: August 20, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.